Locations

Immatics operates as a transatlantic organization with the team spanning from Tübingen and Munich, Germany to Houston, Texas. The long-term integration of the European and US sites also brings the advantage that Immatics has built a highly functioning team across two continents with access to two important markets for medical innovation.

Since its foundation in 2000 as a spin out from H.G. Rammensee’s laboratory at University of Tübingen, Germany, Immatics has revolutionized the identification of tumor-associated pHLA targets, which are recognized by T cells. Identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the subsequent discovery, selection, and engineering of a therapeutic TCR are central to Immatics‘ mission: Delivering the power of T cells to cancer patients and advance the next wave in cancer immunotherapy.

In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.